Atreca Presents Promising Findings from Lead Antibody Program at Society for Immunotherapy of Cancer (SITC) Annual Meeting

On November 11, 2016 Atreca, Inc., a biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response, reported positive preclinical findings generated using the Company’s Immune Repertoire Capture (IRC) technology, presented at the SITC (Free SITC Whitepaper) 2016 Annual Meeting, which is taking place in National Harbor, Maryland, November 9-13, 2016 (Press release, Atreca, NOV 11, 2016, View Source [SID1234522962]). In a poster titled, "Immune Profiling of an Elite Responder Following Checkpoint Inhibitor Therapy Reveals Functional Anti Tumor Antibodies Within Expanded IgG Lineages," a research team including scientists at Atreca and collaborators at a leading institution reported key research findings, including:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Atreca’s IRC technology generated diverse antibodies from the active immune response of an individual with Stage 4 melanoma who had experienced long-term non-progression of disease following cancer regimens including anti-CTLA4 immunotherapy. These antibodies were sequenced from the patient’s blood plasmablasts, activated B cells that play a critical role in immune responses.
In in vitro assays, antibodies were shown to selectively bind tumor tissue but not normal tissue and to bind tumor types beyond the cancer type of the original patient.
Select antibodies demonstrated in vitro tumor killing through antibody-dependent cellular cytotoxicity (ADCC).
"Atreca is pioneering next-generation approaches to cancer immunotherapy based on our ability to elucidate the repertoire of cancer patient antibodies and T cell receptors (TCRs) contributing to positive outcomes," stated Daniel Emerling, Ph.D., Atreca’s Senior Vice President, Research. "In our presentation at SITC (Free SITC Whitepaper), we reported sequencing of over 2500 plasmablasts and identification of clonal antibody families from one exceptional cancer responder. By generating natively paired antibody heavy and light chain sequences, we were able to confirm the ability of a patient’s antibodies to target tumor cells and destroy them, including tumor types unrelated to that of the patient."

"Atreca is advancing a pipeline of therapeutic candidates that can drive and focus the activity of immune responses in cancer immunotherapy, particularly those unleashed by checkpoint inhibitors and immune activators," said Tito A. Serafini, Ph.D., Atreca’s President, Chief Executive Officer, and Co-Founder. "We are thrilled to present data highlighting the power and productivity of our platform at one of the leading cancer immunotherapy conferences. Our lead program is rapidly advancing in preclinical in vivo studies, and we look forward to further progress of our additional programs across multiple indications."

For more information on Atreca’s product portfolio, please visit View Source